A Study to Test the Efficacy and Safety of Padsevonil as Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy — DUET

Drug-Resistant Epilepsy Clinical Trial

Official title:
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects With Drug-Resistant Epilepsy

Status Terminated

Clinical Trial Summary

The purpose of the study is to evaluate the efficacy, safety and tolerability of the 3 selected dose regimens of padsevonil (PSL) administered concomitantly with up to 3 anti-epileptic drugs (AEDs) compared with placebo for treatment of observable focal-onset seizures in subjects with drug-resistant epilepsy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03739840
Study type	Interventional
Source	UCB Pharma
Contact
Status	Terminated
Phase	Phase 3
Start date	March 6, 2019
Completion date	September 28, 2020

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03893916` - MEG Versus EEG HR for the Localization of the Epileptogenic Zone as Part of the Pre-surgical Assessment of Epilepsy	N/A
Completed	`NCT03373383` - Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy	Phase 2
Terminated	`NCT03370120` - Study to Test the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy	Phase 2
Recruiting	`NCT05769634` - Electrophysiological Read-Out of Interoceptive Processing	Early Phase 1